Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

2.

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.

Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators., Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM.

JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120.

3.

Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.

Wills AM, Pérez A, Wang J, Su X, Morgan J, Rajan SS, Leehey MA, Pontone GM, Chou KL, Umeh C, Mari Z, Boyd J; NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators..

JAMA Neurol. 2016 Mar;73(3):321-8. doi: 10.1001/jamaneurol.2015.4265.

PMID:
26751506
4.

Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.

Bega D, Kim S, Zhang Y, Elm J, Schneider J, Hauser R, Fraser A, Simuni T.

J Parkinsons Dis. 2015;5(4):773-82. doi: 10.3233/JPD-150668.

PMID:
26639661
5.

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

NINDS NET-PD Investigators..

Neurology. 2006 Mar 14;66(5):664-71. Epub 2006 Feb 15.

PMID:
16481597
6.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators..

JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

7.

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Fahn S; Parkinson Study Group..

J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. Review.

PMID:
16222436
8.

No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.

Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB Jr, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O.

PLoS One. 2014 Dec 8;9(12):e112287. doi: 10.1371/journal.pone.0112287. eCollection 2014.

9.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group..

Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.

PMID:
15262734
10.

Parkinson's disease severity and use of dopaminergic medications.

Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL; NINDS NET-PD Investigators..

Parkinsonism Relat Disord. 2015 Mar;21(3):297-9. doi: 10.1016/j.parkreldis.2014.10.016. Epub 2014 Dec 15.

11.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group..

Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30.

PMID:
24123224
12.

Creatine for Parkinson's disease.

Xiao Y, Luo M, Luo H, Wang J.

Cochrane Database Syst Rev. 2014 Jun 17;(6):CD009646. doi: 10.1002/14651858.CD009646.pub2. Review.

PMID:
24934384
13.

Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.

Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O.

PLoS One. 2015 Jul 14;10(7):e0133002. doi: 10.1371/journal.pone.0133002. eCollection 2015.

14.
15.

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.

Jankovic J, Hunter C.

Parkinsonism Relat Disord. 2002 Mar;8(4):271-6.

PMID:
12039422
16.

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.

LeWitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group.; SP715 Study Group..

J Neural Transm (Vienna). 2013 Jul;120(7):1069-81. doi: 10.1007/s00702-012-0925-5. Epub 2012 Dec 4.

17.

Rankin scale as a potential measure of global disability in early Parkinson's disease.

Simuni T, Luo ST, Chou KL, Fernandez H, He B, Parashos S.

J Clin Neurosci. 2013 Sep;20(9):1200-3. doi: 10.1016/j.jocn.2012.10.030. Epub 2013 Jun 26.

18.

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C.

Lancet. 2014 Feb 8;383(9916):533-40. doi: 10.1016/S0140-6736(13)62106-6. Epub 2013 Nov 1. Erratum in: Lancet. 2014 Jul 5;384(9937):28.

PMID:
24183563
19.

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators..

Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13.

20.

Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.

Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW.

Expert Opin Pharmacother. 2015;16(10):1423-33. doi: 10.1517/14656566.2015.1049597. Epub 2015 May 22.

PMID:
25997442

Supplemental Content

Support Center